BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mitsuhashi A, Matsui H, Usui H, Nagai Y, Tate S, Unno Y, Hirashiki K, Seki K, Shozu M. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71-77. [PMID: 18723551 DOI: 10.1093/annonc/mdn552] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
Number Citing Articles
1 Ueda Y, Enomoto T, Kimura T, Miyatake T, Yoshino K, Fujita M, Kimura T. Serum biomarkers for early detection of gynecologic cancers. Cancers (Basel) 2010;2:1312-27. [PMID: 24281117 DOI: 10.3390/cancers2021312] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
2 Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer. PLoS One 2014;9:e96384. [PMID: 24801872 DOI: 10.1371/journal.pone.0096384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
3 Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E. Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 2009; 15(42): 5249-5259 [PMID: 19908331 DOI: 10.3748/wjg.15.5249] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
4 Lin YS, Liu YF, Chou YE, Yang SF, Chien MH, Wu CH, Chou CH, Cheng CW, Wang PH. Correlation of chitinase 3-like 1 single nucleotide polymorphisms and haplotypes with uterine cervical cancer in Taiwanese women. PLoS One 2014;9:e104038. [PMID: 25203433 DOI: 10.1371/journal.pone.0104038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
5 Zhao T, Su Z, Li Y, Zhang X, You Q. Chitinase-3 Like-protein-1 function and its role in diseases. Signal Transduct Target Ther. 2020;5:201. [PMID: 32929074 DOI: 10.1038/s41392-020-00303-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
6 Dasari S, Wudayagiri R, Valluru L. Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 2015;445:7-11. [PMID: 25773118 DOI: 10.1016/j.cca.2015.03.005] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 11.7] [Reference Citation Analysis]
7 Michels G, Topalidis T, Büttner R, Engels M, Pfister R. Usefulness of imprint and brushing cytology in diagnosis of lung diseases with flexible bronchoscopy. J Clin Pathol 2012;65:649-53. [DOI: 10.1136/jclinpath-2012-200707] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
8 Cantó E, Reverter F, Morcillo-suárez C, Matesanz F, Fernández O, Izquierdo G, Vandenbroeck K, Rodríguez-antigüedad A, Urcelay E, Arroyo R, Otaegui D, Olascoaga J, Saiz A, Navarro A, Sanchez A, Domínguez C, Caminero A, Horga A, Tintoré M, Montalban X, Comabella M. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis. Mult Scler 2012;18:983-90. [DOI: 10.1177/1352458511433063] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
9 Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V. CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 2013;57:99-105. [PMID: 24222276 DOI: 10.1007/s12026-013-8459-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
10 Wang X, Cai C, Xu J, Jin H, Xu Z. Increased expression of chitinase 3-like 1 is a prognosis marker for non-small cell lung cancer correlated with tumor angiogenesis. Tumor Biol 2015;36:901-7. [DOI: 10.1007/s13277-014-2690-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
11 Comabella M, Fernández M, Martin R, Rivera-Vallvé S, Borrás E, Chiva C, Julià E, Rovira A, Cantó E, Alvarez-Cermeño JC, Villar LM, Tintoré M, Montalban X. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133:1082-93. [PMID: 20237129 DOI: 10.1093/brain/awq035] [Cited by in Crossref: 184] [Cited by in F6Publishing: 176] [Article Influence: 15.3] [Reference Citation Analysis]
12 Väänänen T, Kallio J, Vuolteenaho K, Ojala A, Luukkaala T, Hämäläinen M, Tammela T, Kellokumpu-lehtinen P, Moilanen E. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker. Scandinavian Journal of Urology 2017;51:367-72. [DOI: 10.1080/21681805.2017.1327885] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
13 Porika M, Tippani R, Mohammad A, Bollam SR, Panuganti SD, Abbagani S. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer. Int J Biol Markers 2011;26:22-6. [PMID: 21319134 DOI: 10.5301/jbm.2011.6352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Roslind A, Palle C, Johansen JS, Christensen IJ, Nielsen HJ, Mosgaard BJ. Prognostic utility of serum YKL-40 in patients with cervical cancer. Scand J Clin Lab Invest 2020;80:687-93. [PMID: 33186077 DOI: 10.1080/00365513.2020.1846209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Huang WS, Lin H, Yeh C, Chen L, Chou Y, Yang S, Liu Y. Correlation of Chitinase 3-Like 1 Single Nucleotide Polymorphisms with Hepatocellular Carcinoma in Taiwan. Int J Med Sci 2017;14:136-42. [DOI: 10.7150/ijms.17754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Ngernyuang N, Shao R, Suwannarurk K, Limpaiboon T. Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer. Pathology 2018;50:293-7. [PMID: 29452694 DOI: 10.1016/j.pathol.2017.09.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
17 Thöm I, Andritzky B, Schuch G, Burkholder I, Edler L, Johansen JS, Bokemeyer C, Schumacher U, Laack E. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 2010;116:4114-21. [PMID: 20564116 DOI: 10.1002/cncr.25196] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
18 Bian B, Li L, Yang J, Liu Y, Xie G, Zheng Y, Zeng L, Zeng J, Shen L. Prognostic value of YKL-40 in solid tumors: a meta-analysis of 41 cohort studies. Cancer Cell Int 2019;19:259. [PMID: 31624472 DOI: 10.1186/s12935-019-0983-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
19 Peng C, Peng J, Jiang L, You Q, Zheng J, Ning X. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res 2010;38:1448-57. [PMID: 20926018 DOI: 10.1177/147323001003800427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
20 Kroksveen AC, Opsahl JA, Guldbrandsen A, Myhr KM, Oveland E, Torkildsen Ø, Berven FS. Cerebrospinal fluid proteomics in multiple sclerosis. Biochim Biophys Acta 2015;1854:746-56. [PMID: 25526888 DOI: 10.1016/j.bbapap.2014.12.013] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
21 Zhang JP, Yuan HX, Kong WT, Liu Y, Lin ZM, Wangs WP, Guo JM. Increased expression of Chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma. Tumour Biol 2014;35:12131-7. [PMID: 25142236 DOI: 10.1007/s13277-014-2518-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
22 Gadducci A, Cosio S, Genazzani AR. Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Critical Reviews in Oncology/Hematology 2011;80:181-92. [DOI: 10.1016/j.critrevonc.2010.11.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
23 Ngernyuang N, Francescone RA, Jearanaikoon P, Daduang J, Supoken A, Yan W, Shao R, Limpaiboon T. Chitinase 3 like 1 is associated with tumor angiogenesis in cervical cancer. Int J Biochem Cell Biol 2014;51:45-52. [PMID: 24691276 DOI: 10.1016/j.biocel.2014.03.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
24 Correale J, Fiol M. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis. Mult Scler 2011;17:521-31. [PMID: 21159721 DOI: 10.1177/1352458510392619] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
25 Kastrup J. Can YKL-40 be a new inflammatory biomarker in cardiovascular disease? Immunobiology 2012;217:483-91. [DOI: 10.1016/j.imbio.2011.04.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
26 Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH. YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 2009;9:8. [PMID: 19134206 DOI: 10.1186/1471-2407-9-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
27 Tamam Y, Gunes B, Akbayir E, Kizilay T, Karaaslan Z, Koral G, Duzel B, Kucukali CI, Gunduz T, Kurtuncu M, Yilmaz V, Tuzun E, Turkoglu R. CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Mult Scler Relat Disord 2021;48:102697. [PMID: 33352356 DOI: 10.1016/j.msard.2020.102697] [Reference Citation Analysis]
28 Cheng D, Sun Y, He H. Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0326-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
29 Mistrangelo M, Senetta R, Racca P, Castellano I, Chiusa L, Bellò M, Ricardi U, Morino M, Cassoni P. A novel biomarker-based analysis reliably predicts nodal metastases in anal carcinoma: preliminary evidence of therapeutic impact. Colorectal Dis 2013;15:1382-91. [PMID: 23692332 DOI: 10.1111/codi.12289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Laengsri V, Kerdpin U, Plabplueng C, Treeratanapiboon L, Nuchnoi P. Cervical Cancer Markers: Epigenetics and microRNAs. Laboratory Medicine 2018;49:97-111. [DOI: 10.1093/labmed/lmx080] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
31 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
32 Che D, Yang Z, Wei H, Wang X, Gao J. The Adler grade by Doppler ultrasound is associated with clinical pathology of cervical cancer: Implication for clinical management. PLoS One 2020;15:e0236725. [PMID: 32777812 DOI: 10.1371/journal.pone.0236725] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Alldredge JK, Tewari KS. Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer. Oncologist 2016;21:576-85. [PMID: 27026677 DOI: 10.1634/theoncologist.2015-0393] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
34 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
35 Yeo IJ, Lee CK, Han SB, Yun J, Hong JT. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharmacol Ther 2019;203:107394. [PMID: 31356910 DOI: 10.1016/j.pharmthera.2019.107394] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
36 Shantha Kumara HMC, Gaita D, Miyagaki H, Yan X, Hearth SA, Njoh L, Cekic V, Whelan RL. Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection. World J Gastrointest Oncol 2016; 8(8): 607-614 [PMID: 27574553 DOI: 10.4251/wjgo.v8.i8.607] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
37 Mathiasen AB, Henningsen KMA, Harutyunyan MJ, Mygind ND, Kastrup J. YKL-40: a new biomarker in cardiovascular disease? Biomarkers in Medicine 2010;4:591-600. [DOI: 10.2217/bmm.10.58] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]